Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Zallio F, et al. Among authors: vallisa d. Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13. Br J Haematol. 2016. PMID: 26763986 Free article. Clinical Trial.
CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG, Pieresca C, Cavanna L, Corbella F, Vallisa D, Federico M, Formisano R, Carotenuto M, Merli F, Callea V, Angrilli F, Silingardi V. Gobbi PG, et al. Among authors: vallisa d. Haematologica. 1996 Nov-Dec;81(6):503-12. Haematologica. 1996. PMID: 9009437 Free article. Clinical Trial.
Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Merli F, Federico M, Avanzini P, Ilariucci F, Stelitano C, Iannitto E, Colombi M, Vallisa D, Santagati G, Picinini L. Merli F, et al. Among authors: vallisa d. Haematologica. 1998 Mar;83(3):217-21. Haematologica. 1998. PMID: 9573675 Free article. Clinical Trial.
Clinical characteristics, treatment outcome and survival of 36 adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per lo Studio dei Linfomi (GISL).
Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C, Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M, Silingardi V. Longo G, et al. Among authors: vallisa d. Haematologica. 1999 May;84(5):425-30. Haematologica. 1999. PMID: 10329921 Free article. Clinical Trial.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G; GISL. Sacchi S, et al. Among authors: vallisa d. Haematologica. 2001 Sep;86(9):951-8. Haematologica. 2001. PMID: 11532623 Free article. Clinical Trial.
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M. Iannitto E, et al. Among authors: vallisa d. Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034. Clin Lymphoma Myeloma. 2009. PMID: 19406724 Clinical Trial.
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: vallisa d. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767089 Free article. Clinical Trial.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
133 results